Table 3 Clinicopathological correlation of DDX3X expression in HCC.
From: Targeting FAM134B-DDX3X axis inhibiting AKT signaling in hepatocellular carcinoma
Characteristics | Total | Non-high expression of DDX3X | High expression of DDX3X | P | |
|---|---|---|---|---|---|
Gender | Male | 103 | 37 | 66 | 0.7987 |
Female | 19 | 6 | 13 | ||
Age | ≤55 years | 77 | 28 | 49 | 0.8448 |
>55 years | 45 | 15 | 30 | ||
Serum Alpha-fetoprotein | <400 ng/ml | 65 | 30 | 35 | 0.0019 |
≥400 ng/ml | 57 | 13 | 44 | ||
Tumor sizea | <5 cm | 48 | 23 | 25 | 0.0212 |
≥5 cm | 74 | 20 | 54 | ||
Cirrhosis | Absent | 33 | 15 | 18 | 0.2004 |
Present | 89 | 28 | 61 | ||
Tumor encapsulation | Absent | 56 | 24 | 32 | 0.1293 |
Present | 66 | 19 | 47 | ||
Pathological vascular invasion | Absent | 74 | 28 | 46 | 0.5613 |
Present | 48 | 15 | 33 | ||
Cancer recurrence | Absent | 60 | 25 | 35 | 0.1850 |
Present | 62 | 18 | 44 | ||
Differentiation grade | High grade | 29 | 13 | 16 | 0.2668 |
Low grade | 93 | 30 | 63 | ||
TNM | Ⅰ-Ⅱ | 87 | 37 | 50 | 0.0112 |
Ⅲ-Ⅵ | 35 | 6 | 29 | ||
Portal vein tumor thrombus | Absent | 101 | 33 | 68 | 0.2155 |
Present | 21 | 10 | 11 | ||
